Achillion plummets on FDA refusal to lift sovaprevir study hold
This article was originally published in Scrip
Executive Summary
Shares of Achillion Pharmaceuticals plummeted more than 45%, losing at least $3.29, in after-hours trading on 27 September after the company said the FDA was refusing to lift the clinical hold on the biotech's Phase I trial testing its experimental hepatitis C virus (HCV) drug sovaprevir (ACH-1625), a pan-genotypic HCV protease inhibitor.